BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Sadra A, Kweon HS, Huh SO, Cho J. Gastroprotective and gastric motility benefits of AD-lico/Healthy Gut™ Glycyrrhiza inflata extract. Anim Cells Syst (Seoul) 2017;21:255-62. [PMID: 30460076 DOI: 10.1080/19768354.2017.1357660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 刘爱茹, 杜奕奇. 我国幽门螺杆菌感染现状和治疗策略的改变. 世界华人消化杂志 2016; 24(32): 4396-4403 [DOI: 10.11569/wcjd.v24.i32.4396] [Reference Citation Analysis]
3 Tarhini M, Fayyad-kazan M, Fayyad-kazan H, Mokbel M, Nasreddine M, Badran B, Kchour G. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. Microbial Pathogenesis 2018;117:23-6. [DOI: 10.1016/j.micpath.2018.02.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870-878. [PMID: 26848181 DOI: 10.1136/gutjnl-2015-311019] [Cited by in Crossref: 108] [Cited by in F6Publishing: 97] [Article Influence: 21.6] [Reference Citation Analysis]
5 Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-Activity Relationship for Sulfonamide Inhibition of Helicobacter pylori α-Carbonic Anhydrase. J Med Chem 2016;59:11098-109. [PMID: 28002963 DOI: 10.1021/acs.jmedchem.6b01333] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
6 Ozturk T, Sengul D, Sengul I. Helicobacter pylori and association between its positivity and anatomotopographic settlement in the stomach with the host age range. Ann Afr Med 2021;20:1-8. [PMID: 33727504 DOI: 10.4103/aam.aam_69_19] [Reference Citation Analysis]
7 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Reference Citation Analysis]
8 Goli YD, Moniri R. Efficacy of probiotics as an adjuvant agent in eradication of Helicobacter pylori infection and associated side effects. Beneficial Microbes 2016;7:519-27. [DOI: 10.3920/bm2015.0130] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Czyrski A. Analytical Methods for Determining Third and Fourth Generation Fluoroquinolones: A Review. Chromatographia 2017;80:181-200. [PMID: 28216694 DOI: 10.1007/s10337-016-3224-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
10 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
11 Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol 2016; 22(11): 3150-3157 [PMID: 27003991 DOI: 10.3748/wjg.v22.i11.3150] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
12 Hathroubi S, Zerebinski J, Ottemann KM. Helicobacter pylori Biofilm Involves a Multigene Stress-Biased Response, Including a Structural Role for Flagella. mBio. 2018;9:e01973-18. [PMID: 30377283 DOI: 10.1128/mbio.01973-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
13 Gong M, Han Y, Wang X, Tao H, Meng F, Hou B, Sun BB, Wang G. Effect of Temperature on Metronidazole Resistance in Helicobacter pylori. Front Microbiol 2021;12:681911. [PMID: 34093508 DOI: 10.3389/fmicb.2021.681911] [Reference Citation Analysis]
14 Poursina F, Fagri J, Mirzaei N, Safaei HG. Overexpression of spoT gene in coccoid forms of clinical Helicobacter pylori isolates. Folia Microbiol (Praha) 2018;63:459-65. [PMID: 29327293 DOI: 10.1007/s12223-017-0557-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Chung JW, Kim SY, Park HJ, Chung CS, Lee HW, Lee SM, Kim I, Pak JH, Lee GH, Jeong JY. In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains. Gut Liver. 2017;11:648-654. [PMID: 28750485 DOI: 10.5009/gnl16503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017;22:e12374. [DOI: 10.1111/hel.12374] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
17 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
18 Zeeb M, Kerrinnes T, Cicin-Sain L, Guzman CA, Puppe W, Schulz TF, Peters A, Berger K, Castell S, Karch A. Seropositivity for pathogens associated with chronic infections is a risk factor for all-cause mortality in the elderly: findings from the Memory and Morbidity in Augsburg Elderly (MEMO) Study. Geroscience 2020;42:1365-76. [PMID: 32648237 DOI: 10.1007/s11357-020-00216-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258 [PMID: 34497448 DOI: 10.3748/wjg.v27.i31.5247] [Reference Citation Analysis]
20 Amadei SS, Notario V. A Significant Question in Cancer Risk and Therapy: Are Antibiotics Positive or Negative Effectors? Current Answers and Possible Alternatives. Antibiotics (Basel) 2020;9:E580. [PMID: 32899961 DOI: 10.3390/antibiotics9090580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 235] [Article Influence: 91.3] [Reference Citation Analysis]
22 Al-Eraky DM, Helmy OM, Ragab YM, Abdul-Khalek Z, El-Seidi EA, Ramadan MA. Prevalence of CagA and antimicrobial sensitivity of H. pylori isolates of patients with gastric cancer in Egypt. Infect Agent Cancer. 2018;13:24. [PMID: 30026792 DOI: 10.1186/s13027-018-0198-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
23 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
24 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111:949-956. [PMID: 27185079 DOI: 10.1038/ajg.2016.182] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]
26 Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res 2016;5:F1000 Faculty Rev-1747. [PMID: 30023042 DOI: 10.12688/f1000research.8598.1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
27 Fahimi F, Tohidkia MR, Fouladi M, Aghabeygi R, Samadi N, Omidi Y. Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy. Bioimpacts 2017;7:59-71. [PMID: 28546954 DOI: 10.15171/bi.2017.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
28 Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci 2016;61:3215-20. [PMID: 27659671 DOI: 10.1007/s10620-016-4305-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
29 Palacios-gorba C, Pina R, Tortajada-girbés M, Jiménez-belenguer A, Siguemoto É, Ferrús MA, Rodrigo D, Pina-pérez MC. Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection. Food Funct 2020;11:4525-34. [DOI: 10.1039/d0fo00768d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
30 Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb 2020;7:87-94. [PMID: 32232212 DOI: 10.14744/nci.2019.62558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]